HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials.

Two international phase III trials-LITESPARK-022 and LITESPARK-011-demonstrate the potential benefits of the HIF-2α inhibitor belzutifan for patients with clear cell renal cell carcinoma. When combined with the PD-1 inhibitor pembrolizumab as an adjuvant treatment, it reduced the risk of disease recurrence by 28% and prolonged disease-free survival over pembrolizumab alone. For patients whose disease returned following immunotherapy, belzutifan and the VEGFR inhibitor lenvatinib bested the VEGFR inhibitor cabozantinib in overall response, progression-free survival, and duration of response.